BioGaia has signed an agreement with Beijing Keyuan Xinhai Pharmaceutical Co Ltd
for the exclusive rights to sell BioGaia’s ProTectis baby drops and ProTectis
and Gastrus tablets through the retail pharmacy channel in China from 2013. The
products will be sold under BioGaia’s own brand.
Beijing Keyuan Xinhai Pharmaceutical Co Ltd (http://www.kyxh.com/en) was founded
in 1995. It is a large pharmaceutical company with business in several areas,
such as hospital drug supply and sales of medical appliances, consumables and
pharmaceuticals. The company is a wholly owned subsidiary of Shanghai
Pharmaceuticals Holding Co. Ltd.
Both the BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain
BioGaia’s patented and well researched probiotic strain Lactobacillus reuteri
Protectis. Today BioGaia’s finished products are available in around 60
countries. BioGaia Gastrus is a new product that is currently being investigated
in patients with Helicobacter pylori infection.
China has a population of over 1.35 billion people. It is the world's second
-largest economy by both nominal total GDP and purchasing power.
“Since last year we have been focusing on getting our products in to the BRIC
markets and I am very happy to see that they now will be available in the
largest of them all. China is of course a market with tremendous potential, but
also with many challenges in terms of achieving sufficient distribution and
penetration, but with Keyuan as our partner we are confident that we will be
successful also in China in the long term”, says Peter Rothschild, President of
BioGaia.
Latest press releases from BioGaia
2013-05-07 BioGaia signs exclusive distribution agreement in South Korea
2013-04-26 Annual General Meeting of BioGaia
2013-04-26 BioGaia AB Interim report 1 January-31 March 2013
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 13 May 2013, 11:15 am
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
